碳青霉烯
铜绿假单胞菌
医学
重症监护医学
多中心研究
微生物学
内科学
抗生素
生物
细菌
随机对照试验
遗传学
作者
Andrea Dessilani,Shaniko Kaleci,Gabriella Orlando,Maurizio Del Monte,Andrea Bedini,Erica Franceschini,Maria Cristina Albertini,L Benassi,Alessandra Oliva,Sergio Mezzadri,M Codeluppi,Lucia Serio,Emanuela Biagioni,Gabriele Melegari,Claudia Venturelli,Mario Sarti,Lesley De Pietri,Massimo Girardis,Cristina Mussini,Marianna Meschiari
标识
DOI:10.1093/jacamr/dlaf046.025
摘要
Abstract Background This study aims to assess the risk factors for clinical failure in carbapenem-intermediate-resistant Pseudomonas aeruginosa (CiRPA) infections, focusing on susceptibility profiles, prior treatments, and the effectiveness of current targeted antibiotic regimens. Methods We conducted a multicenter, retrospective cohort study of adults with microbiologically confirmed CiRPA infections (any sites) admitted to four large tertiary care university hospital between January 2018 to December 2024. Three comparison groups were defined: i) intermediate meropenem (MEM) minimum inhibitory concentration (MIC, 4-8 μg/ml) vs. resistant (>8 μg/ml); ii) active monotherapy vs. active combination therapy; iii) ceftolozane/tazobactam (C/T) vs. the best available therapy (BAT) among a subgroup of patients with pneumonia or bloodstream infection (BSI). The primary outcome was clinical success, a composite one defined as defined as survival at 30-days, resolution of signs and symptoms of infection at the end of therapy, and the absence of recurrent infection due to P. aeruginosa within 90-day. Results A total of 197 eligible patients were included: 99 (50%) pneumonia and 31 (16%) BSI. Intensive care unit (ICU) admission was required for 127 patients (65%), and 72 (36%) presented with sepsis or septic shock. C/T and ceftazidime-avibactam (CZA) were the most used antibiotics, accounting for 25% and 15% of treatments, respectively. No significant differences in clinical success were observed between patients with intermediate or resistant meropenem profiles (48.39% vs. 48.48%; p = 0.989) or between those treated with C/T comparing to the BAT (47.50% vs. 37.93%; p = 0.308), even with continuous infusion or bolus administration. In the multivariate analysis, prior use of anti-Pseudomonas cephalosporins and ventilator-associated were identified as significant predictors of clinical failure (OR 2.28, 95% CI 1.16-4.49, and 3.42, 95% CI 1.7-6.89, respectively). Conclusions No significant clinical success advantage was observed for the intermediate susceptibility profile, combination therapy, or C/T use in CRPA infections. Prior use of anti-Pseudomonas cephalosporins together with VAP infections resulted significant predictors of clinical failure including recurrent infection, highlighting the independent role of antimicrobial stewardship in improving clinical outcomes for patients with Pseudomonas aeruginosa infections. Larger studies are needed to confirm these findings and optimize therapeutic strategies for CRPA infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI